• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺动脉高压的定义、分类和诊断。

Definition, classification and diagnosis of pulmonary hypertension.

机构信息

Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Ludwig Boltzmann Institute for Lung Vascular Research Graz, Graz, Austria.

出版信息

Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01324-2024. Print 2024 Oct.

DOI:10.1183/13993003.01324-2024
PMID:39209475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11533989/
Abstract

Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of mean pulmonary arterial pressure (mPAP) >20 mmHg, assessed by right heart catheterisation. Pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) distinguish pre-capillary PH (PAWP ≤15 mmHg, PVR >2 Wood Units (WU)), isolated post-capillary PH (PAWP >15 mmHg, PVR ≤2 WU) and combined post- and pre-capillary PH (PAWP >15 mmHg, PVR >2 WU). Exercise PH is a haemodynamic condition describing a normal mPAP at rest with an abnormal increase of mPAP during exercise, defined as a mPAP/cardiac output slope >3 mmHg/L/min between rest and exercise. The core structure of the clinical classification of PH has been retained, including the five major groups. However, some changes are presented herewith, such as the re-introduction of "long-term responders to calcium channel blockers" as a subgroup of idiopathic pulmonary arterial hypertension, the addition of subgroups in group 2 PH and the differentiation of group 3 PH subgroups based on pulmonary diseases instead of functional abnormalities. Mitomycin-C and carfilzomib have been added to the list of drugs with "definite association" with PAH. For diagnosis of PH, we propose a stepwise approach with the main aim of discerning those patients who need to be referred to a PH centre and who should undergo invasive haemodynamic assessment. In case of high probability of severe pulmonary vascular disease, especially if there are signs of right heart failure, a fast-track referral to a PH centre is recommended at any point during the clinical workup.

摘要

肺动脉高压(PH)是一种血流动力学状态,其特征为平均肺动脉压(mPAP)升高>20mmHg,通过右心导管术进行评估。肺小动脉楔压(PAWP)和肺血管阻力(PVR)可区分前毛细血管 PH(PAWP≤15mmHg,PVR>2 伍德单位(WU))、孤立性后毛细血管 PH(PAWP>15mmHg,PVR≤2WU)和前、后毛细血管混合 PH(PAWP>15mmHg,PVR>2WU)。运动性 PH 是一种血流动力学状态,描述静息时 mPAP 正常,但运动时 mPAP 异常升高,定义为静息和运动之间 mPAP/心输出量斜率>3mmHg/L/min。PH 的临床分类的核心结构已保留,包括五个主要组。然而,这里也提出了一些变化,例如将“长期钙通道阻滞剂反应者”重新引入特发性肺动脉高压作为一个亚组,在 2 组 PH 中增加亚组,并根据肺部疾病而不是功能异常对 3 组 PH 亚组进行区分。丝裂霉素 C 和卡非佐米已被添加到与 PAH 有“明确关联”的药物列表中。对于 PH 的诊断,我们提出了一种逐步方法,主要目的是区分那些需要转诊到 PH 中心并进行有创血流动力学评估的患者。在存在严重肺血管疾病的高概率情况下,特别是如果存在右心衰竭的迹象,建议在临床评估的任何阶段都快速转诊到 PH 中心。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ccf/11533989/fd9fb4ea3427/ERJ-01324-2024.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ccf/11533989/5ee749d89b17/ERJ-01324-2024.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ccf/11533989/fd9fb4ea3427/ERJ-01324-2024.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ccf/11533989/5ee749d89b17/ERJ-01324-2024.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ccf/11533989/fd9fb4ea3427/ERJ-01324-2024.02.jpg

相似文献

1
Definition, classification and diagnosis of pulmonary hypertension.肺动脉高压的定义、分类和诊断。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01324-2024. Print 2024 Oct.
2
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.血流动力学定义和肺动脉高压的最新临床分类。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
3
Revisiting Pulmonary Hypertension in the Era of Temporary Mechanical Circulatory Support - Literature Review and Case-Based Discussion.重新审视临时机械循环支持时代的肺动脉高压——文献回顾与病例讨论。
Transplant Proc. 2023 Dec;55(10):2462-2469. doi: 10.1016/j.transproceed.2023.09.022. Epub 2023 Nov 18.
4
Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.左心疾病所致肺动脉高压的临床表型和结局:毛细血管前成分的作用。
PLoS One. 2018 Jun 19;13(6):e0199164. doi: 10.1371/journal.pone.0199164. eCollection 2018.
5
The Diagnostic Challenge of Group 2 Pulmonary Hypertension.2型肺动脉高压的诊断挑战
Prog Cardiovasc Dis. 2016 Jul-Aug;59(1):22-9. doi: 10.1016/j.pcad.2016.05.003. Epub 2016 May 16.
6
[Vaskuläre Dyspnoe: Pulmonale Hypertonie].[血管性呼吸困难:肺动脉高压]
Ther Umsch. 2023 Aug;80(6):272-278.
7
[New definition and classification of pulmonary hypertension].[肺动脉高压的新定义与分类]
Pneumologie. 2023 Nov;77(11):854-861. doi: 10.1055/a-2145-4648. Epub 2023 Nov 14.
8
Diagnostic Performance of Pulmonary Capacitance at Rest and During Exercise in Idiopathic Pulmonary Arterial Hypertension.特发性肺动脉高压患者静息和运动时肺电容的诊断性能
Heart Lung Circ. 2019 Feb;28(2):289-294. doi: 10.1016/j.hlc.2017.10.019. Epub 2017 Nov 8.
9
Combined pre- and post-capillary pulmonary hypertension: The clinical implications for patients with heart failure.合并毛细血管前和毛细血管后肺动脉高压:心力衰竭患者的临床意义。
PLoS One. 2021 Mar 2;16(3):e0247987. doi: 10.1371/journal.pone.0247987. eCollection 2021.
10
Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension.射血分数降低的心力衰竭合并肺动脉高压患者运动时的肺血管反应。
Eur J Heart Fail. 2015 Mar;17(3):320-8. doi: 10.1002/ejhf.217. Epub 2014 Dec 30.

引用本文的文献

1
Evaluation of pulmonary hypertension in heart failure with preserved ejection fraction.射血分数保留的心力衰竭患者肺动脉高压的评估
Heart Fail Rev. 2025 Sep 9. doi: 10.1007/s10741-025-10553-8.
2
Advances in diagnosis and patient profiling in pulmonary arterial hypertension for precision medicine.肺动脉高压精准医学中诊断与患者特征分析的进展
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251367312. doi: 10.1177/17534666251367312. Epub 2025 Aug 29.
3
The role of Na,K‑ATPase in lung diseases (Review).钠钾ATP酶在肺部疾病中的作用(综述)

本文引用的文献

1
Embracing the challenges of neonatal and paediatric pulmonary hypertension.拥抱新生儿和儿科肺动脉高压的挑战。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01345-2024. Print 2024 Oct.
2
Pulmonary hypertension associated with left heart disease.与左心疾病相关的肺动脉高压。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01344-2024. Print 2024 Oct.
3
Treatment algorithm for pulmonary arterial hypertension.肺动脉高压治疗算法。
Mol Med Rep. 2025 Nov;32(5). doi: 10.3892/mmr.2025.13665. Epub 2025 Aug 29.
4
Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病中肺血管功能障碍的意义
Pulm Circ. 2025 Aug 18;15(3):e70144. doi: 10.1002/pul2.70144. eCollection 2025 Jul.
5
The Role of Obstructive Sleep Apnea in Pulmonary Hypertension Associated with Lung Diseases (Group 3 Pulmonary Hypertension): A Narrative Review.阻塞性睡眠呼吸暂停在与肺部疾病相关的肺动脉高压(第3组肺动脉高压)中的作用:一篇叙述性综述
J Clin Med. 2025 Aug 1;14(15):5442. doi: 10.3390/jcm14155442.
6
Ginsenoside Rg1 Ameliorates Pulmonary Hypertension by Inhibiting cGAS/STING Mediated Cell Senescence.人参皂苷Rg1通过抑制cGAS/STING介导的细胞衰老改善肺动脉高压。
Drug Des Devel Ther. 2025 Jul 29;19:6487-6504. doi: 10.2147/DDDT.S527938. eCollection 2025.
7
Important Differences in Disease Severity, Echocardiography Findings, and Referral Delays in Non-Hispanic Black Patients With Pulmonary Arterial Hypertension.非西班牙裔黑人肺动脉高压患者在疾病严重程度、超声心动图检查结果及转诊延迟方面的重要差异
Pulm Circ. 2025 Jul 28;15(3):e70138. doi: 10.1002/pul2.70138. eCollection 2025 Jul.
8
Sound Waves Versus Pressure Waves: The Increasing Role of Echocardiography and Noninvasive Vasoreactivity Testing in Pediatric Pulmonary Hypertension Management.声波与压力波:超声心动图和无创血管反应性测试在儿童肺动脉高压管理中日益重要的作用
Echocardiography. 2025 Aug;42(8):e70254. doi: 10.1111/echo.70254.
9
Oxidative Stress and Inflammation in Hypoxemic Respiratory Diseases and Their Comorbidities: Molecular Insights and Diagnostic Advances in Chronic Obstructive Pulmonary Disease and Sleep Apnea.低氧性呼吸系统疾病及其合并症中的氧化应激与炎症:慢性阻塞性肺疾病和睡眠呼吸暂停的分子见解与诊断进展
Antioxidants (Basel). 2025 Jul 8;14(7):839. doi: 10.3390/antiox14070839.
10
Pulmonary Artery Pulsatility Index: A Novel Marker for Risk Assessment and Prognosis in Pediatric Idiopathic Pulmonary Arterial Hypertension.肺动脉搏动指数:小儿特发性肺动脉高压风险评估和预后的新型标志物
Pediatr Cardiol. 2025 Jul 25. doi: 10.1007/s00246-025-03970-x.
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01325-2024. Print 2024 Oct.
4
Pulmonary hypertension associated with lung diseases.与肺部疾病相关的肺动脉高压。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01200-2024. Print 2024 Oct.
5
Clinical Response to Pulmonary Arterial Hypertension Treatment Does Not Depend on Pulmonary Arterial Wedge Pressure: A Meta-Analysis Using Individual Participant Data from Randomized Clinical Trials.肺动脉高压治疗的临床反应不取决于肺动脉楔压:一项使用随机临床试验个体参与者数据的荟萃分析
Am J Respir Crit Care Med. 2024 Sep 15;210(6):844-847. doi: 10.1164/rccm.202403-0612RL.
6
Pulmonary arterial wedge pressure in healthy subjects: a meta-analysis.健康受试者肺动脉楔压的荟萃分析。
Eur Respir J. 2024 Aug 15;64(2). doi: 10.1183/13993003.00967-2024. Print 2024 Aug.
7
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.与蛋白酶体抑制剂相关的肺动脉高压患者的特征及预后
Eur Respir J. 2024 Jun 28;63(6). doi: 10.1183/13993003.02158-2023. Print 2024 Jun.
8
"This Patient Needs a Doctor, Not a Guideline!" The Zone of Uncertainty in Pulmonary Arterial Wedge Pressure Measurement.“这位患者需要的是医生,而非指南!”肺动脉楔压测量中的不确定性区域
Am J Respir Crit Care Med. 2024 Sep 15;210(6):712-714. doi: 10.1164/rccm.202402-0359VP.
9
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.肺动脉高压的血管反应性阳性检测:现代管理时代的治疗后果、治疗模式和结局。
Circulation. 2024 May 14;149(20):1549-1564. doi: 10.1161/CIRCULATIONAHA.122.063821. Epub 2024 Apr 12.
10
Association of Cardiopulmonary Hemodynamics and Mortality in Veterans With Liver Cirrhosis: A Retrospective Cohort Study.心肺血液动力学与退伍军人肝硬化患者死亡率的相关性:一项回顾性队列研究。
J Am Heart Assoc. 2024 Apr 16;13(8):e033847. doi: 10.1161/JAHA.123.033847. Epub 2024 Apr 3.